[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"small-for-gestational-age\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:small-for-gestational-age":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,44,90,121,144,168],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100616742","phase-3-the-efficacy-and-safety-of-inpegsomatropin-injection-in-children-with-short-stature-born-small-for-gestational-age-100616742",false,"NCT07309562","The Efficacy and Safety of Inpegsomatropin Injection in Children With Short Stature Born Small for Gestational Age","A Multicenter, Randomized, Open-Label, Active-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of Inpegsomatropin Injection, s.c Once a Week, Compared With Recombinant Human Growth Hormone (rhGH) Injection in Children With Short Stature Born Small for Gestational Age（SGA）","Inclusion Criteria:\n\n* Prepubertal (Tanner stage I) children: boys aged ≥2 and \\\u003C11 years, and girls aged ≥2 and \\\u003C10 years at screening.\n* Bone age is not more than 1 year advanced or more than 2 years delayed compared to chronological age (i.e., -2 years ≤ bone age - chronological age ≤ 1 year).\n* Birth weight and\u002For length below the 10th percentile for gestational age and sex, according to the reference values in Appendix 1.\n* Gestational age at birth ≥28 weeks.\n* Height at screening below -2 SD for age and sex, according to the reference values in Appendix 2.\n* Body mass index (BMI) between the 5th and 95th percentiles for age and sex, according to the reference values in Appendix 3.\n* Peak GH level ≥10.0 ng\u002FmL in at least one prior GH stimulation test.\n* No prior systemic growth-promoting therapy (used continuously for ≥1 month), including but not limited to growth hormone, insulin-like growth factor-1 (IGF-1), etc.\n* Legal guardian has provided written informed consent. If the participant is ≥8 years old, they must also provide written assent. For participants under 8 years old who are capable of expressing agreement, their assent should be formally documented.\n\nExclusion Criteria:\n\n* Subjects with closed epiphyses.\n* Subjects with other types of growth abnormalities, including confirmed or highly suspected growth hormone deficiency (GHD), Noonan syndrome, Prader-Willi syndrome, Russell-Silver syndrome, Turner syndrome, short stature due to GH receptor deficiency, short stature due to growth plate-related gene abnormalities (e.g., SHOX gene anomalies), growth retardation due to malnutrition, or growth retardation due to hypothyroidism.\n* Participation in any other clinical trial with drug or non-drug interventions within 3 months prior to screening.\n* Use of inhaled corticosteroids for more than 2 consecutive weeks, or oral\u002Fintravenous corticosteroids for more than 1 consecutive week, within 3 months prior to screening.\n* Current or long-term requirement for therapies that may affect growth, including but not limited to methylphenidate, sex hormones, gonadotropin-releasing hormone analogs, aromatase inhibitors, anabolic agents, or insulin.\n* Abnormal liver or kidney function at screening (ALT \\> 1.5 times the upper limit of normal \\[ULN\\], Cr \\> ULN).\n* Diagnosis of diabetes mellitus, or two consecutive fasting blood glucose measurements ≥ 6.1 mmol\u002FL prior to randomization.\n* Chronic infectious diseases which, in the investigator's judgment, may affect study participation (e.g., chronic hepatitis B).\n* Systemic chronic diseases, such as chronic kidney disease, severe cardiovascular diseases, or psychiatric\u002Fpsychological disorders.\n* Congenital skeletal dysplasia, scoliosis exceeding 15°, limping gait, or a prior diagnosis of slipped capital femoral epiphysis.\n* History of intracranial hypertension.\n* Past or current history of malignant tumors, including intracranial tumors.\n* Known allergy to growth hormone or any of its excipients.\n* Any other condition deemed by the investigator as inappropriate for participation in this clinical trial.","ALL","2 Years","11 Years",{"count":20,"type":21},141,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","This is a multicenter, randomized, open-label, active-controlled Phase III clinical trial to evaluate the efficacy and safety of Inpegsomatropin injection，once a week，compared with recombinant human growth hormone (rhGH) in children with short stature born small for gestational age (SGA).It plans to enroll 141 children with short stature born small for gestational age (SGA), who will be stratified by gender and age and randomized in a 1:1:1 ratio to either Experimental Group 1, Experimental Group 2, or the Active Control Group. All participants will undergo a screening period (up to 12 weeks), a treatment period (52 weeks), and a post-treatment follow-up period (5 weeks). Safety and efficacy will be comprehensively evaluated.",[27],"Small for Gestational Age",[29,30],"Inpegsomatropin Injection","Recombinant Human Growth Hormone Injection","RECRUITING","2026-05-07",{"date":34,"type":35},"2026-05-08","ACTUAL",{"date":37,"type":35},"2026-01-20",{"date":39,"type":21},"2028-05-07",{"name":41,"class":42},"Xiamen Amoytop Biotech Co., Ltd.","INDUSTRY",49,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":58,"conditions":59,"keywords":65,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":4},"100635484","phase-3-periodontal-disease-and-small-vulnerable-newborns-in-rural-nepal-a-community-based-trial-100635484","NCT07553286","Periodontal Disease and Small Vulnerable Newborns in Rural Nepal: A Community-based Trial","Periodontal Disease and Small Vulnerable Newborns in Rural Nepal: A Community-based Randomized Trial","Inclusion Criteria:\n\n* Married women of reproductive age (15-35 years).\n* Living in the study area who are pregnant and consent to participate.\n\nExclusion Criteria:\n\n* Currently pregnant women.\n* Women who are sterilized or use long-acting contraceptive methods or are divorced or widowed.\n* Women identified as pregnant ≥12 gestational weeks based upon date of last menstrual period.",true,"FEMALE","15 Years","35 Years",{"count":56,"type":21},2280,[24],"Periodontal disease in pregnant women has been implicated as a potential risk factor for adverse pregnancy outcomes, including being born preterm, small-for-gestational age, and\u002For low birth weight. Infants who have at least one of these outcomes, known as small vulnerable newborns (SVN)), are at increased risk of early death and poor infant growth and development. Rigorous, high-quality randomized trials are needed to evaluate whether improving the periodontal health of pregnant women can reduce the risk of adverse pregnancy outcomes in areas like South Asia, where these outcomes are common and neonatal mortality remains high. This study is a community-based, randomized controlled trial (n=2,280) to evaluate a package of oral health interventions delivered to pregnant women in the first trimester until delivery on the incidence of SVNs in rural Sarlahi District, Nepal. The intervention package will include a daily antiseptic oral rinse and intensive oral hygiene education and instruction. Both intervention and control groups will be provided a manual toothbrush and toothpaste. The investigators will determine intervention effects on incidence of SVNs and individual outcomes of preterm birth, small-for-gestational age, and low birth weight. In a biospecimen sub-study (n=200), the investigators will collect venous blood, gingival crevicular fluid, and plaque in early and late pregnancy to explore relationships between subgingival inflammation, systemic inflammation, and SVN types and other adverse pregnancy outcomes. If efficacious, a low-cost package of oral health interventions - including an antiseptic oral rinse, intensive oral hygiene education and instruction, and provision of a manual toothbrush and toothpaste - could improve maternal and newborn outcomes at this critical time of growth and development.",[60,61,62,63,64],"Preterm Birth","Low Birth Weight","Small Vulnerable Newborn","Small-for-gestational Age","Periodontal Disease",[66,67,68,69,70,71,72,73,74,75,76,77,78],"Nepal","Oral health","Small Vulnerable Newborns","Preterm birth","Periodontal disease","Low birth weight","Small-for-gestational age","Pregnancy","Antenatal care","Dental health","Gingivitis","Antiseptic oral rinse","Oral hygiene","NOT_YET_RECRUITING","2026-04-27",{"date":82,"type":35},"2026-05-01",{"date":84,"type":21},"2026-07-01",{"date":86,"type":21},"2028-12-31",{"name":88,"class":89},"Johns Hopkins Bloomberg School of Public Health","OTHER",{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":51,"sex":52,"minAge":98,"maxAge":99,"enrollmentInfo":100,"targetDuration":4,"studyType":102,"phases":4,"briefSummary":103,"conditions":104,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":120},"100336573","investigating-the-structured-use-of-ultrasound-scanning-for-fetal-growth-100336573","NCT03662178","Investigating the Structured Use of Ultrasound Scanning for Fetal Growth","Investigating the Structured Use of Ultrasound Scanning for Fetal Growth (Oxford Growth Restriction Identification Programme (OxGRIP)) on Risk Factors for and the Incidences of Adverse Maternal, Fetal and Neonatal Outcome","OxGRIP","Inclusion Criteria:\n\n• All pregnant women receiving antenatal care at the Oxford University Hospitals NHS Foundation Trust (OUHFT) from January 2013 to 31st December 2019 with no exclusion criteria\n\nExclusion Criteria:\n\n* Women who have opted out of research related to pregnancy in this pregnancy whilst receiving care by the OUHFT.\n* If intrapartum care takes place outside of the OUHFT.","16 Years","60 Years",{"count":101,"type":21},56000,"OBSERVATIONAL","Fetal growth restriction during pregnancy represents one of the biggest risk factors for stillbirth (Gardosi et al, 2013), with 'about one in three term, normally formed antepartum stillbirths are related to abnormalities of fetal growth' (MBRRACE, 2015).\n\nTherefore, antenatal detection of growth restricted babies is vital in order to be able to monitor and decide the appropriate delivery timing.\n\nHowever, antenatal detection of SGA babies has been poor, varying greatly across trusts in England in those that calculate their rates (NHS England, 2016). Most trusts do not calculate their detection rates and rates are therefore unknown. It is estimated that routine NHS care detects only 1 in 4 growth restricted babies (Smith, 2015).\n\nOxford University Hospitals NHS Foundation Trust, in partnership with the Oxford Academic Health Science Network (AHSN) has introduced a clinical care pathway (the Oxford Growth Restriction Pathway (OxGRIP)) designed to increase the rates of detection of these at risk babies. The pathway is intended to increase the identification of babies who are at risk of stillbirth, in order to try to prevent this outcome, whilst making best usage of resources, and restricting inequitable practice and unnecessary obstetric intervention.\n\nIt has been developed with reference to a body of research, however, the individual parts of care provided have not been put together in a pathway in this manner before. Therefore it is important to examine whether the pathway meets its goals of improving outcomes for babies in a 'real world' setting.\n\nThe principles of the pathway are\n\n1. A universal routine scan at 36 weeks gestation.\n2. Additional growth scans at 28 and 32 weeks gestation based on a simplified assessment of risk factors and universal uterine artery Doppler at 20 weeks gestation.\n3. Assessment of further parameters other than estimated fetal weight associated with adverse perinatal outcome (eg growth velocity, umbilical artery Doppler and CPR).\n\nThe clinical data routinely collected as a result of the introduction of the pathway offers a valuable and unique resource in identifying and analysing in the effects of the pathway on its intended outcomes and also in investigating and analysing other maternal, fetal and neonatal complications and outcomes, establishing normal \u002F reference ranges for ultrasound values.",[105,106,107,27,108,109,110],"Stillbirth","Fetal Death","Fetal Growth Retardation","Fetal Growth Restriction","Perinatal Death","Intrauterine Growth Restriction","2026-01-27",{"date":113,"type":35},"2026-01-29",{"date":115,"type":35},"2017-09-01",{"date":117,"type":21},"2029-09-30",{"name":119,"class":89},"Oxford University Hospitals NHS Trust",1,{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":51,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":127,"targetDuration":4,"studyType":102,"phases":4,"briefSummary":129,"conditions":130,"keywords":4,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":4},"100603237","accuracy-of-interstitial-continuous-glucose-sensors-in-neonates-100603237","NCT07133906","Accuracy of Interstitial Continuous Glucose Sensors in Neonates","Inclusion Criteria:\n\n* women aged 18 years or older\n* speaks English, Spanish, Portuguese, or Haitian Creole\n* pregnant \\>24 weeks gestation with singleton pregnancy\n\nExclusion Criteria:\n\n* known concomitant maternal or fetal condition which, in the opinion of the investigator, could present a risk to the safety or welfare of the subject or study staff\n* plans to deliver at a hospital other than Women and Infants Hospital of Rhode Island",{"count":128,"type":21},114,"Low blood sugar in newborns is common and if prolonged or untreated may place them at increased risk for later learning and behavior challenges. Currently, we measure newborn glucose with at least four painful heel sticks, missing one in four episodes of low blood sugar. The goal of this observational study is to develop a less invasive approach to glucose monitoring, developed for newborns, that provides more frequent glucose measurements. We will also measure how a pregnant woman's health impacts newborn glucose, and how newborn glucose is linked to brain oxygen saturation and development.",[131,132,133,63,134],"Neonatal Hypoglycemia","Gestational Diabetes","Maternal Obesity Complicating Pregnancy","Large-for-gestational Age","2025-08-13",{"date":137,"type":35},"2025-08-21",{"date":139,"type":21},"2025-09",{"date":141,"type":21},"2027-06",{"name":143,"class":89},"Women and Infants Hospital of Rhode Island",{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":4,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":151,"targetDuration":153,"studyType":102,"phases":4,"briefSummary":154,"conditions":155,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":120},"100423808","long-term-safety-and-effectiveness-of-growtropin-ii-treatment-in-children-with-short-stature-100423808","NCT04798690","Long-term Safety and Effectiveness of Growtropin®-II Treatment in Children With Short Stature","Open, Multi-center, Non-interventional, Prospective\u002F Retrospective Observational Study on Long-term Safety and Effectiveness of Growtropin®-II Treatment in Children With Short Stature","Inclusion Criteria:\n\n* Children with short stature by growth hormone deficiency(GHD) or idiopathic short stature (ISS) or turner's syndrome(TS) or small for gestational age(SGA)\n* Children who has official height record at least 6 months prior\n\nExclusion Criteria:\n\n* Children with Epiphyseal closure",{"count":152,"type":21},2500,"10 Years","This study evaluates long-term safety and effectiveness of Growtropin®-II treatment in children with short stature.",[156,157,158,27],"Growth Hormone Deficiency","Idiopathic Short Stature","Turner Syndrome","2023-04-11",{"date":161,"type":35},"2023-04-12",{"date":163,"type":35},"2021-02-08",{"date":165,"type":21},"2031-12",{"name":167,"class":42},"Dong-A ST Co., Ltd.",{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":176,"targetDuration":4,"studyType":102,"phases":4,"briefSummary":178,"conditions":179,"keywords":181,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":120},"100178992","long-term-safety-and-effectiveness-of-growth-hormone-with-ghd-ts-crf-sga--iss-and-pws-in-children-100178992","NCT01604395","Long-term Safety and Effectiveness of Growth Hormone With GHD, TS, CRF, SGA , ISS and PWS in Children","An Open, Multi-center, Prospective and Retrospective Observational Study to Evaluate the Long-term Safety and Effectiveness of Growth Hormone (Eutropin Inj. \u002F Eutropin Plus Inj.) Treatment With GHD, TS, CRF, SGA, ISS and PWS in Children","LGS","Inclusion Criteria:\n\n* short stature children aged 2 years or more\n* children with GHD,TS, CRF, SGA or ISS\n* written informed consent from the person, person's parent or legal guardian",{"count":177,"type":21},6000,"The purpose of this study is to evaluate the long-term safety and effectiveness of growth hormone (Eutropin Inj.\u002FEutropin plus Inj.) treatment with GHD (Growth Hormone Deficiency), TS (Turner Syndrome),CRF (Chronic Renal Failure), SGA (Small for Gestational Age), and ISS (Idiopathic Short Stature).",[156,158,180,27,157],"Chronic Renal Failure",[182,183,184,185,186,187],"GHD","TS","CRF","SGA","ISS","PWS","2021-02-17",{"date":190,"type":35},"2021-02-21",{"date":192,"type":4},"2012-01",{"date":194,"type":21},"2032-12-31",{"name":196,"class":42},"LG Chem"]